VolitionRx Limited (VNRX) - Gross Profitability

Official company branding of VolitionRx (VNRX)

The development of VolitionRx Limited (VNRX) relies on a sovereign implementation cycle for molecular tests, rendering the business resilient to market volatility. Strategic alliances with US clinics are accelerating the commercialization of Nu.Q diagnostics and software. Analyzing the gross profit margin on the GURU.Markets chart time series, where 67.90 is recorded as the baseline value, reveals stable margins driven by the integration of check-ups into annual examinations.

Gross Profitability: VolitionRx Ltd. (VNRX) for 07/04/2022 - 11/20/2026

Comprehensive metric breakdowns and analytics for volition.com (VNRX)

- current quotes and average value forecast:
Fundamental valuation:VNRX - volition.com
Mass-produced product of VolitionRx Limited

Gross margin, equal to 67.90, is calculated as the portion of revenue minus direct production costs, measuring the efficiency of cost-of-goods-sold management. For VolitionRx Limited (VNRX), which is investing in the commercialization of cancer tests while sustaining chronic losses, the gross profit margin serves as an indicator of the business's potential scalability before achieving positive free cash flow.